LIQUIDIA_Logo.jpg
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
07 janv. 2019 07h00 HE | Liquidia Technologies, Inc.
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
LIQUIDIA_Logo.jpg
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
31 oct. 2018 07h00 HE | Liquidia Technologies, Inc.
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...